<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02181946</url>
  </required_header>
  <id_info>
    <org_study_id>1100.1361</org_study_id>
    <nct_id>NCT02181946</nct_id>
  </id_info>
  <brief_title>Effects of Nevirapine on the Steady State Pharmacokinetics of Fluconazole in HIV Positive Patients</brief_title>
  <official_title>An Open-label Study in HIV+ Patients to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Fluconazole (DIFLUCAN®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the effects of nevirapine on the steady state
      pharmacokinetics of fluconazole and to assess the steady-state pharmacokinetics of nevirapine
      when given in combination with fluconazole.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <primary_completion_date type="Actual">July 2001</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum concentration of the analyte in plasma (Cmax)</measure>
    <time_frame>up to day 40</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum concentration of the analyte in plasma (Cmin)</measure>
    <time_frame>up to day 40</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve over the dosing interval (AUCτ)</measure>
    <time_frame>up to day 40</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of Cmax (Tmax)</measure>
    <time_frame>up to day 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral clearance (Cl/F)</measure>
    <time_frame>up to day 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 40 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal changes in laboratory parameters</measure>
    <time_frame>up to day 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in vital signs</measure>
    <time_frame>up to day 39</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Fluconazole with and without Nevirapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <arm_group_label>Fluconazole with and without Nevirapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <arm_group_label>Fluconazole with and without Nevirapine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients between the ages of 18 and 65 years who are seropositive for
             HIV-1 antibody by an ELISA test and confirmed by an alternative method, e.g. Western
             Blot

          -  CD4 + cell count ≥ 100 cells/mm3

          -  Patients who meet the following laboratory parameters

               -  Granulocyte count &gt; 1000 cells/mm3

               -  Hemoglobin &gt; 9.0 g/dl (men and women)

               -  Platelet count &gt; 75,000 cells/mm3

               -  Alkaline phosphatase &lt; 3.0 times the upper limit of normal

               -  Aspartame Transaminase (AST) and Alanine Transaminase (ALT) &lt; 3.0 times the upper
                  limit of normal

               -  Total bilirubin &lt; 1.5 times the upper limit of normal

          -  Female patients of childbearing potential must be willing to use a reliable form of
             contraception which must include a medically approved from of barrier contraception

          -  Patients able to provide written informed consent and comply with study requirements

        Exclusion Criteria:

          -  Female patients who are pregnant or breast-feeding

          -  Seated systolic blood pressure below 100 mmHg, or greater than 160 mmHg, and/or heart
             rate less than 50 or greater than 100 beats/min

          -  History of drug allergy or known drug hypersensitivity

          -  Patients receiving any investigational drug, antineoplastic agent or radiotherapy
             other than local skin radiotherapy treatment within 12 weeks before starting study
             medication

          -  Patients requiring systemic treatment with corticosteroids or drugs known to be
             hepatic enzyme inducers or inhibitors within 28 days of study entry (Study Day 1).
             Such substances in these categories include: macrolide antibiotics (e.g. erythromycin,
             clarithromycin, azithromycin, dirithromycin), azole antifungals (e.g. itraconazole),
             rifabutin and phenytoin

          -  Patients requiring systemic treatment with CYP3A4 (cytochrome P450 3A4) substrates
             such as terfenadine, astemizole, cisapride, triazolam and midazolam during the course
             of the trial

          -  Use of protease inhibitors or non-nucleoside reverse transcriptase inhibitors within
             28 days of Study Day 1 or during the trial

          -  Patients with a current history of intravenous drug abuse, alcohol or substance abuse
             (within the last year)

          -  History of any clinically important disease including hepatic, renal, cardiovascular
             or gastrointestinal disease

          -  Patients with malabsorption, severe chronic diarrhea or patients unable to maintain
             adequate oral intake
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

